Identification of Diagnostic Markers for Major Depressive Disorder Using Machine Learning Methods

Vortioxetine versus placebo for treatment of major depressive disorder

Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...

Clinical use of the diagnostic criteria for major depressive disorder.

In this Issue of Epidemiology and Psychiatric Sciences two Editorials discuss the epidemiological and clinical implications of the current diagnostic criteria for major depressive disorder (MDD). Considering that the term ‘diagnosis’ is usually used to indicate an attempt at classification of an individual’s condition into separate and distinct categories that allow clinical decisions about pro...

Sheehan’s Syndrome Presenting as Major Depressive Disorder

Sheehan’s syndrome or Simmond’s disease is a rare endocrine disorder seen in clinical practice. The clinical spectrum is diverse and a high index of suspicion together with a good clinical acumen and proper diagnostic approach helps in early diagnosis and prompt treatment of this endocrinopathy. Sheehan’s syndrome presenting as a major depressive disorder finds less mention in the literature.Th...

Biological Markers and Genetic Factors of Major Depressive Disorder

Identifying Early Maladaptive Schema of Patients with Major Depressive Disorder

Cognitive models of depression propose that negative schemas and Early Maladaptive Schema contribute to depressive symptoms. The purpose of this study is to identify the early maladaptive Schema of patients with depression disorder. The method of study is descriptive. Research statistics involves all patients with depression disorder who have come to the c...